{
  "docId": "019de515-df71-7068-a98d-cc2a99c8892d",
  "docSlug": "c88233ba648814c9f5b65afc1926df6d",
  "documentTitle": "Adagio Therapeutics | Investor Conference Presentation Deck | 11 slides",
  "authorId": "adagio-therapeutics",
  "authorName": "Invivyd",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 8,
  "pageCount": 11,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "overcrowded",
  "nDataPoints": 5,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de515-df71-7068-a98d-cc2a99c8892d/8",
  "deckHref": "/decks/019de515-df71-7068-a98d-cc2a99c8892d",
  "deckJsonHref": "/decks/019de515-df71-7068-a98d-cc2a99c8892d.json",
  "deckAnchorHref": "/decks/019de515-df71-7068-a98d-cc2a99c8892d#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.41,
        "w": 0.939,
        "x": 0.031,
        "y": 0.201
      },
      "kind": "diagram",
      "text": "Healthy Adult Volunteers (N=30)\n8:2 Randomization (VYD222:Placebo)\nVYD222 Dose A (n=8)\nVYD222 Dose B (n=8)\nVYD222 Dose C (n=8)\nPlacebo (n=6)\nDay 1 (Dosing)\nEarly Safety, Tolerability, PK & sVNA Data\nMonth 12 (Last visit)\nLong Term Follow Up Data",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cdad6b79-8057-410e-8016-f8593d171bbe",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.16,
        "w": 0.44,
        "x": 0.518,
        "y": 0.726
      },
      "kind": "list",
      "text": "Dose-ranging trial will evaluate three different doses, each administered as a single IV push. All doses are designed to provide durability in the face of viral evolution and flexibility at the time of regulatory submission.\nTrial is designed to potentially enable rapid advancement into a pivotal Phase 3 trial.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a447b2cc-5163-47d8-9e12-fa7dc757bad0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.16,
        "w": 0.44,
        "x": 0.044,
        "y": 0.726
      },
      "kind": "list",
      "text": "Primary: Safety and tolerability through 12 months\nSecondary: Pharmacokinetic (PK) and immunogenicity assessments\nExploratory: Serum virus neutralizing activity (sVNA)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c4e08fcd-b9a6-4104-ba04-f774d83fbdc2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.013,
        "w": 0.36,
        "x": 0.044,
        "y": 0.954
      },
      "kind": "source-note",
      "text": "Source: Clinicaltrials.gov (NCT05791318); IV, intravenous",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "43b3da84-d755-48d6-a6ea-8bba46441478",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.025,
        "w": 0.16,
        "x": 0.044,
        "y": 0.68
      },
      "kind": "title",
      "text": "OBJECTIVES:",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "685f5c75-81ed-4541-a8fa-436240e6dc76",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.025,
        "w": 0.302,
        "x": 0.518,
        "y": 0.68
      },
      "kind": "title",
      "text": "KEY DESIGN ELEMENTS:",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e51cb6eb-63e8-4eaf-9f97-158a7ad67ad2",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 10,
      "from": 7,
      "name": "Jobs To Be Done",
      "slug": "53-jobs-to-be-done",
      "bestFor": "Product innovation, market entry, competitive positioning",
      "matchId": "3b35d58f-2d99-44a5-b484-2bf12410ffb9",
      "evidence": "Slides 7-10 discuss market sizing, ongoing trials, and proposed solutions.",
      "position": 1,
      "objective": "How can Invivyd's VYD222 address the unmet need?",
      "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit",
      "confidence": 0.7,
      "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}